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Metabolic disorders are not well-recognized by psychiatrists as a possible source of
secondary psychoses. Inborn errors of metabolism (IEMs) are not frequent. Although their
prompt diagnosis may lead to suitable treatments. IEMs are well-known to pediatricians,
in particular for their most serious forms, having an early expression most of the time.
Recent years discoveries have unveiled later expression forms, and sometimes very
discreet first physical signs. There is a growing body of evidence that supports the
hypothesis that IEMs canmanifest as atypical psychiatric symptoms, even in the absence
of clear neurological symptoms. In the present review, we propose a detailed overview
at schizophrenia-like and autism-like symptoms that can lead practitioners to bear in
mind an IEM. Other psychiatric manifestations are also found, as behavioral, cognitive,
learning, and mood disorders. However, they are less frequent. Ensuring an accurate IEM
diagnosis, in front of these psychiatric symptoms should be a priority, in order to grant
suitable and valuable treatment for these pathologies.
Keywords: IEMs, neurometabolic disorders, homocysteine, urea, organic psychosis, schizophrenia-like,
atypicalness
Introduction
The Neurometabolic Diseases (NMDs), also known as Inborn Errors of Metabolism (IEMs), are
genetic disorders affecting, for most of them, the conversion of a substrate into a product by an
enzyme.
An insufficient enzyme production can cause the accumulation of the substrate and the absence
or depletion of the final expected product. The mechanisms and metabolic processes are obviously
much more complex than this simple description. Some pathologies in particular, do not fully meet
that definition. Although, this simplified representation may warrant a reasonable explanation to
the extreme diversity of organ damages found in the NMDs. Indeed, the absence of an essential
product from birth, or the accumulation of deleterious product may have a massive impact on the
brain. This pathological situation not only can explain the frequency of neurological or psychiatric
signs, but also the presence of anomalies found in other organs, or vice versa. Altered intracellular
concentrations is a common physiopathological core on several NMDs, derive from an altered
synthesis or a modified catabolism.
Main interest for psychiatrist is the fact that some diseases may emerge with psychiatric signs
with no other associated symptoms. Neurological soft signs can appear later, after many years of
active psychotic presentation.
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Once the metabolic disease is recognized, it is possible to
adopt simple therapeutic strategies. For some conditions, this
may imply dietary changes in order to avoid non-degradable
substrate accumulation, or increasing the intake of an absent
product, sometimes a humble vitamin.
Moreover, advances are made in enzyme therapy. The
simplicity of the therapeutic plan should be a call to all
practitioner for acquiring a better knowledge, and thus
recognition, of these treatable diseases.
In this paper, we will introduce some of the NMDs having
psychiatric clinical presentation and a potential improvement
when receiving suitable treatment. We are going to focus
on NDMs leading to schizophrenia like symptoms and some
developmental disorders.
Methods
Data sources has been explored on published literature
(MEDLINE sources) inspecting Disorders of Homocysteine
Metabolism (DHMs): cystathionine beta-synthase deficiency
[CbS-D] and methyltetrahydrofolate reductase deficiency
[MTHFR-D], acute porphyria (POR), urea cycle disorders
(UCD), cerebrotendinous-xanthomatosis (CTX), Wilson disease
(WD), and Niemann-Pick disease type C (NP-C).
Literature scrutiny included all case reports, case series
and reviews accounting for original data reporting psychiatric
symptoms and cognitive impairments, between a data range from
January 1967 and June 2014. A four-step standardized strategy
was applied for the selection process.
Selected items were screened for the presence of psychiatric
signs and symptoms as key features of disease, natural history,
severity and treatments.
A final selection over 619 documents was retained.
Documents analyses were conducted as follow: CbS-D (n = 6),
MRHFR-D (n = 4), UCD (n = 8), POR (n = 12), CTX (n = 16),
NP-C (n = 9). Inclusion was also made for six non-systematic
literature published reviews. A lack of explicit description of
psychiatric symptoms was observed over several published
reports.
All relevant findings will be presented in a didactic
perspective, through key features for each disease, the presence of
psychiatric symptoms and particular sings suggesting a possible
IEM leading to secondary psychosis or developmental events.
Neurometabolic Disease and
Schizophrenia Spectrum Disorder
Schizophrenia presents an estimated prevalence of 1% of the
general population (Barbato, 1998). Nowadays, there is a
widespread knowledge about the fact that patients suffering from
schizophrenia have enlarged risks of somatic medical conditions.
Complex metabolic syndromes, accounting for hyperglycaemia,
dyslipidemia, along with higher global cardiovascular risk
for acute myocardial infarction, are listed among the many
organic conditions associated with schizophrenic disorders
(Price and Ron, 2003). A non-negligent part of these metabolic
pathologies can be induced by antipsychotic treatments, as
hyperprolactinemia and overweight, but others, as cerebro
vascular accidents, are suspected to be facilitated by endothelium
specific diseases, not fully understood to date (Harris et al., 2008).
Given the extreme complexity of comorbid interactions, it may
become difficult to know the exact proportion of these metabolic
disorders exhibited by patients in all schizophrenia cases.
The literature review mentions a study conducted on
268 patients, affording 6% prevalence for all organic causes
potentially linked to psychotic symptoms (Johnstone et al., 1987).
NMDs are accounted among all pathologies, although they are
considered as rare diseases, probably under estimated at 4/10,000
in the general population (Applegarth et al., 2000). However,
some of them are treatable, which allow us to highlight the
interest to know how to make an accurate diagnosis (Bonnot
et al., 2014) (Table 1).
Disorders of Homocysteine Metabolism
(DHMs)
Two pathologies linked to the absence of two distinct enzymes
fall into this group: Cystathionine beta synthase deficiency (CbS)
and methyltetrahydrofolate reductase deficiency (MTHFR).
Hyperhomocystinuria due to CbS deficiency has a prevalence
estimated at 1/350,000 births, being an autosomal recessive
condition. CbS usually converts homocysteine to cystathionine
with the help of three cofactors including vitamin B12 and folic
acid. The accumulation of homocysteine is responsible for highly
variable clinical features including skeletal abnormalities as a
knock-knees or pes cavus, sometimes associated with scoliosis
and osteoporosis. One of the morphotypes is a Marfan-like
habitus (large size and thinness). Thromboembolic disorders of
small or great vessels were presented in 25% of a sample of 15
patients. There are also eye disorders, as lenticular ectopia (in
85% of cases) and severe myopia. Intellectual Disability (ID) is
common but not constant.
These signs are frequently associated with psychiatric mood
disorders and anxiety disorders. Obsessive compulsive disorder
has been reported on half of this population (Abbott et al., 1987),
Schizophrenic-like disorders are also possible and can be an
isolated clinical feature (Li and Stewart, 1999).
Homocystinuria related to MTHFR deficiency is an autosomal
recessive defect caused by a mutation in the MTHFR gene
[1p36.3]. The absence of the enzyme prevents the remethylation
of homocysteine to methionine, and therefore leads to a hyper-
homocystinemia and hypo-homocystinuria. Usually, it manifests
through early severe neurological signs a apnea, microcephaly
and seizures. MTHFR deficiency can also have a late expression
while combining Intellectual Disability, ataxia, and schizophrenic
like disorders.
Schizophrenic symptoms are often very productive with
polymorphic and often visual hallucinations. Several cases are
described in the literature (Mattson and Shea, 2003; Roze et al.,
2003; Gilbody et al., 2007). The psychotic outburst is usually
insidious, but can be dramatically prompted during a post-
surgical episode. Roze describes the case of a 16 years old girl,
with a dissociative state, having an altered course of though and
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TABLE 1 | List of seven NMDs organic and psychiatric symptoms.
Core clinical features, diagnosis and treatment hints
Disorder Organic symptoms Psychiatric symptoms Trigger event Biomarkers Treatment
Homocysteinemia Thrombolembolism Intellectual disabilities Protein diet Homocysteinimia
[CbS] Scoliosis Mood disorders Post-surgery Methioninemia
Marfan-like habitus OCD
Cerebellar signs Schizophrenia-like sx
Homocysteinemia Apnea* Intellectual Disabilities High (Met) diet Homocysteinimia Vitamin B12
[MTHFR] Seizures* Visual hallucinations Methioninemia Diet**
Microcephaly Schizophrenia-like sx Pyroxine
Ataxia
Urea cycle Abdominal pain Mood disorders Protein diet Hyperammoniemia Diet**
disorders [UCDs] Confusion Intense hallucinations Post-surgery
Nausea/vomiting Drugs***
Porphyiria Black/red urine Schizophrenia-like sx Periodic outburst PBG in urine IV hemin
[POR] Abdominal pain Delusions ALA in blood IV carbohydrate
Constipation Hallucinations
Nausea/vomiting Course of though dist.
Hepatic disturb. Catatonia
Erythropoietic disturb. Mood disorders
Confusion
Wilson disease Tremor Mood disorders Ceruloplasmin copper
[WD] Dystonia Personality changes chelation
Dysarthria Schizophrenia-like sx
Hallucinations +++
Kayser-Fleischer ring Altered cognitif Fx
Niemann-Pick SNP + + + Autism-like sx Incidious Skyn biopsy Myglustat
disease type C Deafness* Schizophrenia-like sx Fibroblast culture
[NP-C] Neonatal jaundice* Visual hallucinations Filipin staining
Dystonia Frontal syndrome [NPC1 and NPC2 gene test]
Ataxia
Dysartria
Dysphagia
Splenomegaly
Cerebrotendinous Xanthomas ADHD MRI signs chenodeoxycholic
xanthomatosis Chronic diarrhea Schizophrenia-like sx High cholestanol Acid
[CTX] Spastic paralysis Mood disorders [CYP27A1 gene test]
Epilepsie* Intellectual disabilities
Ataxia Cognitive decline
Polyneuropathy
Juvenile cataract
NMDs, Neurometabolic disorders; OCD, Obsessive compulsive disordes; Met, Methionine; SNP, Supranuclear Palsy; ADHD, Attention Deficit Hyperactive Disorder; MRI, Magnetic
Resonance Imaging; sx, symptoms; dist, disturbances. Bold values correspond to noticeable organic or psychiatric symptoms.
*Early symptoms after birth or childhood.
**Protein restriction diet, ***Trigger drugs reported are corticosteroids and valproic acid.
visual and auditory hallucinations, during 3 months. She used
to be a responsible student without major difficulties and did
not exhibit any abnormal development trait before the onset
of the dissociative state. During the psychiatric interview, only
one organic sign was reported: a recent urinary incontinence.
Neurological examination revealed an areflective paraparesia and
a right plantar extension reflex. Further diagnosis explorations
and complete neurological examination were carried out due
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to familiar history of MTHFR deficiency on the older sister,
24 years old.
Diagnosis is based on amino acids chromatography and
the determination of homocysteine. It is then shaped by the
sequencing of the gene.
Treatment consists on the association of folate and vitamin
B12, or a diet low in methionine/rich in cysteine. Pyroxine can
be administered among some patients that reveal to be good
responders. These kinds of measures were applied on the 16
years old girl, allowing a significant improvement. Antipsychotic
medication was not needed.
Urea Cycle Disorders (UCDs)
The urea cycle is themetabolic process allowing nitrogen removal
from the body. The lack of one of the six enzymes involved in
this cycle interrupts the process and causes the accumulation of
nitrogen in the form of hyperammonemia. The prevalence of
six pathological conditions related to the urea cycle disorders
is 1/8000 births. The intensity of the disturbance is related
to the magnitude of the enzyme deficiency. There are milder
forms usually involving nausea, vomiting, headache, especially on
subjects under high protein diets. Corticosteroids and valproic
acid can also worsen the symptoms. Psychiatric signs are not
uncommon and may emerge as mood disorders or intense
episodic hallucinations (auditory and visual), appearing at acute
or subacute periods (Arn et al., 1990; Myers and Shook, 1996;
Bachmann, 2003; Enns et al., 2005; Krivitzky et al., 2009; Thurlow
et al., 2010). The combination of acute visual hallucinations
and vomiting in a context of the introduction of medication
or high protein content diet, can lead to suspect an UCD. We
have found in the literature a case report of delayed diagnosis
due to clinical presentation of anorexia nervosa (Legras et al.,
2002).
Diagnosis should be a simple and inexpensive ammonia assay.
Main interest on performing an accurate analysis is to introduce
a suitable treatment by dietary protein restriction. Some case
reports have described mortal consequences of diagnosis delay
on psychiatric patients having acute noisy symptoms (Panlaqui
et al., 2008).
Acute Porphyria
Porphyrias are a group of eight NMDs causing intermittent
neuro-visceral and cutaneous attacks, concomitant or
isolated. All porphyrias are generated by enzymes deficit of
heme metabolism, leading to an aggregation of porphyrin
or its precursors [delta-aminolevulinic acid (ALA) and
porphibilinogène (PBG)]. This accumulation is essentially
localized in the liver and bone marrow. The prevalence of
these disorders is estimated at 5.4/1,000,000. Clinical signs
usually appear in adults, although it is not uncommon to find
childhood forms. Two porphyria types are known: hepatic or
erythropoietic. Both types can encompass chronic courses in the
absence of any psychiatric sign. However, acute hepatic forms
may manifest by severe abdominal pain, along with nausea,
vomiting and constipation, and neurological and psychiatric
symptoms.
The diagnosis is based on the measurement of ALA on blood
test and PBG in urine. Treatment consists of injection of human
hemin and carbohydrates infusion.
The literature on cases of psychiatric events is large and
reflects a recurrence of 24–70% over acute patients (Goldberg,
1959; Cashman, 1961; Stein and Tschudy, 1970; Brodie et al.,
1977; Bonkowsky and Schady, 1982; Tishler et al., 1985; Boon
and Ellis, 1989; Mandoki and Sumner, 1994; Kuhnel et al.,
2000; Gross et al., 2002). Frequent clinical founds consist on
delusions, psychotic traits as hallucinations, course of thought
disorders, and mood disorders (namely depressive type). Some
authors even consider that delusion states are as frequent as
40% on patients with acute porphyria (Bonkowsky and Schady,
1982).
A number of cases are particularly illustrative. Santosh and
Malhotra (1994) reported a case: 14 years old boy with discrete
neurological or organic signs and normal laboratory and imagery
results. The patient endured six episodes, more or less severe,
and usually escorted by organic minor compounds that were
in a way “hidden” by the intensity of psychiatric symptoms.
Episodes consisted on a large variety of symptoms, going from
disorientation, muteness, echolalia, delusions, hallucinations,
hypomania, and even catatonia. Another author describes a
similar case in a 50 year old adult (Crimlisk, 1997). However,
after a retrospective case review based on the emergency services
medical report, it was found recurrent abdominal complains,
headache or nausea.
Wilson Disease
Wilson disease is, as for previously described NMDs, an
autosomal recessive condition. Even though WD is more
common (6/100,000). It is due to the mutation of a gene [ATP7B]
encoding for a copper transportation protein, leading to a copper
accumulation in the liver, kidney, bones, and brain. The current
diagnosis is made on MRI indicating thalamic and lenticular
nucleus hyper-signals. Basal ganglia hypo-densities are present
in only 25% of subjects. Blood copper measurement and the
existence of a conventional Kayser-Fleisher ophthalmic ring,
allow easy diagnostic clues. The treatment is based on copper
chelation.
Psychiatric symptoms are early symptoms, concerning about
two-thirds of all this population (Barthel and Markwardt, 1975;
Dening and Berrios, 1990; Schwartz et al., 1993). In general, it
has been estimated that one in two patients present psychiatric
signs, some authors say one of five, in the absence of any
other organic sign (Dening and Berrios, 1989). Three types of
psychiatric symptoms are frequently cited on the literature, with
a possible simultaneous expression: (i) Mood disorders are the
most common sign in terms of psychiatric disorders, including
both depressive and manic elements: (Medalia and Scheinberg,
1989; Akil et al., 1991; Dening, 1991; Akil and Brewer, 1995;
Srinivas et al., 2008); (Ii) Personality changes are common,
particularly with the emergence of irritability and aggressive
behavior (Barthel and Markwardt, 1975; Coscia et al., 1975);
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(Iii) less common, but not less severe, the schizophrenia-like
symptoms, usually with catatonic presentation (Barthel and
Markwardt, 1975; Renaud et al., 1975; Dening, 1985; Dening and
Berrios, 1989; Dening, 1991). An initial report published on Akil
and Brewer (1995) founded a 10% frequency of Wilson Disease
having schizophrenic-like disorders. Amore recentmeta-analysis
has outlined a 2.4% frequency (Taly et al., 2007).
However, hallucinations are often reported and they are
considered, by far, as the more recurrent psychiatric symptom
(Sagawa et al., 2003; Wichowicz et al., 2006; Spyridi et al.,
2008; Stiller et al., 2008). Early diagnosis is particularly
important due to consequences on school and learning. Complex
cognitive disorders involving executive functions, memory and
neuro-visual., are commonly reported on Wilson’s disease
patients.
Antipsychotic treatments represent a main frustration. It is
often said, in a large number of reports, that antipsychotics
exacerbate psychiatric disorders, which can also be a warning
sign to make an active search of WD diagnosis. First
and foremost, there is an increased risk of developing
antipsychotics neurological side effects (Tu, 1981). Second
generation antipsychotics are less concerned than first generation
ones. Electroconvulsive therapy has proven to be an effective
therapeutic alternative, and may be indicated in front of massive
antipsychotics side effects or hepatic insult (Shah and Kumar,
1997).
Niemann Pick Type C Disease (NPC)
The NPC is an autosomal recessive disease associated with
a mutation of the NPC1 gene in 95% of cases and NPC2
on 4%. The metabolic mechanism is more complex than for
other pathologies mentioned in this article, due to the absence
of enzyme deficiency. Indeed, mutations produce a defect in
the intracellular transport of cholesterol, glycosphingolipids
and sphingosine, leading to their abnormal storage inside the
lysosomal compartment. The accumulation is found in various
tissues, particularly in the liver and spleen for derived unesterified
cholesterol and gangliosides GM2 and GM3 in the brain.
Therefore, clinical presentation is extremely diverse with a
plenitude of non-specific symptoms.
Early signs can come out before the age of 10 years, mainly
neurological. Although, many diagnoses are made on systemic,
non-specific isolated signs as neonatal jaundice or splenomegaly.
Late diagnoses, sometimes up to 70 years, have very different
presentations, and psychiatric signs are not rare. It is estimated
that the age of onset of neurological signs is a key element.
Usually, non-infantile forms are presented by neurological signs
of ataxia type dysarthria, dysphagia, deafness, or cataplexy.
One of the most important signs is supra-nuclear gaze palsy
(SNP), constituting an early and almost always presenting sign.
Although simple, the SNP is often not explored during medical
examination. Eye movements are possible if the examiner asks
the patient to follow his finger or a pen, but they become
impossible when the subject attempts to do it spontaneously.
The diagnosis is made by skin biopsy, Filipin staining test
and fibroblast culture. Drug treatment is Miglustat, slowing the
progression of the disease (Patterson et al., 2007; Bonnot et al.,
2011).
The development of psychiatric symptoms is therefore an
exceptional opportunity for early diagnosis and treatment
(Vanier, 2010).
NPC cases exhibiting schizophrenia like disorders, without
neurological signs, have been reported in the literature. These
are not uncommon in clinical practice (for a review see Bonnot
et al., 2011). Additionally, there were some interesting cases of
schizophrenia with developmental history of autism spectrum-
like disorders (Sandu et al., 2009).
In most cases, visual hallucinations are a crucial finding,
although this is quite an unusual sign in the classical forms
of schizophrenia. Despite the absence of a typical cognitive
profile in these patients, the existence of a frontal syndrome is
often found, namely through a lack of interpersonal distance.
This excessive familiarity can be an early alerting clinical signal
(Klarner et al., 2007).
Cerebrotendinous Xanthomatosis (CTX)
The CTX is an autosomal recessive pathology altering the
synthesis of bile acid. It is caused by a mutation of the CYP27A1
gene, located on the long arm of chromosome 2. This gene
encodes the 27-sterol-hydroxylase involved in the synthesis
of cholic and chenodeoxycholic acids. Al altered synthesis
of these products, facilitates the accumulation of cholesterol
and cholestanol in the brain and tissues, particularly tendons.
Xanthomas, consisting on lipids accumulation in the superficial
dermis, are a visible core clinical sign. Its prevalence is estimated
at 2/100,000 (Bonnot et al., 2010).
The classic clinical presentation is a variable combination of
childhood developmental disabilities, juvenile cataracts, chronic
diarrhea and epilepsy. Neurological decline and psychiatric
symptoms often appear during adolescence. The neurological
signs are often a progressive spastic paraparesis, cerebellar ataxia,
polyneuropathy, and cognitive impairment. Tendon xanthomas
are not rare, constituting a clear distinctive sign. MRI shows
a typical dendritic hyper-signal on cerebellar nuclei regions.
Diagnosis confirmation is made by plasma cholestanol measures
and gene sequencing.
Acute schizophrenic like episodes have been described.
Although, other behavioral disorders are largely more frequent
amid childhood and adolescence, especially Attention Deficit
Hyperactivity Disorders (ADHD) (Sedel et al., 2007). Altogether,
psychiatric symptoms concern around 10% of CTX patients,
under diverse forms including depression, psychosis, and ADHD
(Fraidakis, 2013).
Treatment is based on chenodeoxycholic acid.
NMDs and Psychiatric Symptoms Overview
Based on collected data and literature review on clinical
observations, we propose a comprehensive list of atypicalness key
signs and useful warning signs leading to the search for organic
pathology, especially a neurometabolic disease.
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Discussion
Schizophrenia spectrum disorders are associated with a
wide variety of diseases, both neurological, immunological,
neuro-metabolic, genetic, endocrinological, as well as other
related conditions induced by medications or toxic substances.
Organic diseases in these cases are called “associated,” while
schizophrenia is “secondary.” It is worthy to highlight the
fact that organicity in psychiatric conditions makes part of
a long date discussion about the origins of mental illness
in general (for a historic overview of this discussion, see
Conrad, 1960; Neumarker, 2001). Indeed, psychiatric diseases
due to organic condition have a distinct recognition DSM
or ICD classification, distinguished from to the so called
“pure” psychiatric diseases. The IEM described below show
that cognitive and symptomatic sequels are common in this
field. Moreover, most of the psychiatric symptoms may decrease
after treatment of organic condition, especially in disease that
affect subjects during development. IEM help us to understand
the multidimensional developmental aspects of the psychiatric
diseases.
The neurometabolic disorders assemble a large number of
diseases, for some of them, unfortunately quite unknown. One
of the major interest on reinforcing communication of the
reality of these pathologies, comes from the existence of specific
medications, some of them new and unfamiliar. The organicity
in psychiatry is recognized as an essential element to explore
in front of any initial psychiatric sing, still somatic explorations
have yet to become a priority on clinical practice. The studies on
the prevalence of organic disorders are rare, mainly because they
face a major structural methodological difficulty. Undoubtedly,
the prevalence of schizophrenic disorders is estimated at 1%
of the general population, while that associated pathologies is
much lower. Although an exhaustive search is not possible.
However, one possible strategy is to approach these data by
subpopulation studies. First, studies must be conducted on early
forms of schizophrenia related symptoms that has been already
reported in association with organic pathologies (Remschmidt
and Theisen, 2012). Then, catatonia outburst on childhood and
adolescence, mostly associated with schizophrenia-like disorders,
for which the largest case series record organic pathologies on
10–15% of cases (Cornic et al., 2009).
Furthermore, it is important to remind the common
association between a genetic dimension and schizophrenia,
given by the 22q11 micro deletion. This condition is estimated
to be present in 1–2% of schizophrenic patients and in 2–4%
for the early onset forms (Vorstman et al., 2006; Hoogendoorn
et al., 2008). Allegedly it is possible to claim the existence of
a significant proportion of patients with schizophrenia related
disorders, associated with undiagnosed organic pathologies,
although it is difficult to determine their prevalence in an
accurate way.
It seems both unrealistic and unnecessary to transform each
psychiatrist into an expert on rare diseases in general and
neurometabolic disorders in particular. Psychiatry is mainly
a clinical discipline, based on observation and the search of
characteristic clinical signs in the search of the most suitable
diagnosis. There are no idiosyncratic unequivocal signs and a
large number of pathologies can share similar clinical features.
Semiology is extremely rich and detailed; it is not infrequent
to spot some signs that are not usually part of a given clinical
picture. We dare to call these clinical signs “atypicalness.”
Most of the atypical signs have been little described, however
we dispose of a handful number of studies investigation
populations of psychotic patients with associated disorders
(schizophrenia and organic pathology without distinction)
(Cutting, 1987; Barak et al., 2002; Horiguchi et al., 2009).
Heterogeneity of the possible co-morbidities between
neurometabolic disorders and psychiatric symptoms could
explain, in a sense, the weakness of available data. It seems
legitimate to imagine that a genetic or chronic disease can
express in diverse manners during an acute episode after
particular food exposure or drug intoxication.
Catatonia is considered as an atypical symptom, even when
exhibited by elder or younger patients. In the literature, it is
often described that visual hallucinations, especially if they are
larger than the acoustic-verbal hallucinations classic, are also very
suggestive of atypicalness. Antipsychotic treatment resistance is
also a frequently found element in some organic conditions. The
existence of adverse drug reactions is a key warning point.
Case reports analyses describe a frequent incidence
of antipsychotic sides effects, especially neurological.
Extrapyramidal effects (akinesia, dystonia, dysarthria, and
other akathisia) are particularly frequent in children under
antipsychotic treatment (Cohen et al., 2012). Some authors
consider that these kinds of side effects could induce a
misunderstanding of the clinical presentation and a delay on the
accurate detection of underneath neurological signs.
Furthermore, the unusual existence of a rapid onset of
psychiatric disorders could be linked to an organic underlying
disease. Other listed warning symptoms are the presence of
intellectual disabilities, not directly associated to a schizophrenia
picture, or a cognitive deterioration in a normal developing child.
Laboratory tests screening for neurometabolic abnormalities
is not recommended for all patients, but they are legitimate in
case of a high suspicion of neurometabolic disorder.
Conclusion
An extensive literature review highlights the fact that it
is not uncommon to find the existence of hidden organic
pathologies, particularly neurometabolic disorders, in association
with psychiatric disorders. A large variety of symptoms has
been reported, as autism-like symptoms, mood and anxious
disorders, as well as behavioral, learning and cognitive disorders.
Schizophrenia like symptoms are by far the most frequent
psychiatric warning sing of neurometabolic disorders. Thus, it is
crucial to make an early detection and diagnosis, especially when
they are treatable, as in the case of the seven NMDs presented in
the present review.
Purportedly, it will be quite useful to formalize a systematic
clinical research in front of psychotic atypical signs and develop
easy and usually low-cost measure, having a potential incidence
on public health and a massive impact on patients’ quality of life.
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